tirzepatide approved in canada Eli Lilly launches weight-loss drug Mounjaro India, beats Novo Nordisk to major market tirzepatide approval in canada 📣

22(6): e13177

(September 2023) Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis (September 2023) As Semaglutides Popularity Soars, Rare but Serious Adverse Effects Are Emerging (November 2023) Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the UglyBenefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying (January 2024) Diabetic gastroparesis: a disease for which long-term therapeutic benefits are difficult to obtain (May 2024) Other Possible Side Effects of Zepbound Explored Tirzepatide, the active ingredient in Zepbound, belongs to a class of drugs called GLP-1 agonists

Moreover, research continues to explore the long-term effects of tirzepatide on weight loss and metabolic health

During the randomized period of the study, 26.3% of adults in the tirzepatide group had a treatment-emergent adverse event related to the drug compared with 10.4% of the placebo group